Management of surgical patients receiving anticoagulation and antiplatelet agents

British Journal of Surgery

Volumn 95, Issue 12, 2008, Pages 1437-1448

  Thachil, J ^a   Gatt, A ^c   Martlew, V ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULATION; ARTIFICIAL HEART; BLEEDING; CLINICAL ASSESSMENT; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SURGICAL PATIENT; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT PLANNING; VENA CAVA FILTER;

ANTICOAGULANTS; ASPIRIN; EMERGENCY TREATMENT; HEPARIN; HUMANS; INTRAOPERATIVE CARE; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; WARFARIN;

EID: 56749163376     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6381     Document Type: Review

References (72)

1. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(Suppl): 429S-456S.
2. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
3. Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N et al. Antithrombotic therapy in valvular heart disease - native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(Suppl): 457S-482S.
4. Fuster V, Ryden LE, Asinger R, Cannom DS, Crijns HJ, Frye RL et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. Am Coll Cardiol 2001; 38: 1231-1266.
5. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506-1511.
6. Heit JA. Perioperative management of the chronically anticoagulated patient. J Thromb Thrombolysis 2001; 12: 81-87.
7. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-17.
8. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2006; 48: e1-e148.
9. Longstreth WT Jr, Bernick C, Fitzpatrick A, Cushman M, Knepper L, Lima J et al. Frequency and predictors of stroke death in 5888 participants in the Cardiovascular Health Study. Neurology 2001; 56: 368-375.
10. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900.
11. Lindberg F, Bergqvist D, Rasmussen I. Incidence of thromboembolic complications after laparoscopic cholecystectomy: review of the literature. Surg Laparosc Endosc 1997; 7: 324-331.
12. Dunn AS, Turpie AGG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med 2003; 163: 901-908.
13. Chee YL, Crawford JC, Watson HG, Greaves M. British Committee for Standards in Haematology. Guideline on the assessment of bleeding risk prior to surgery or invasive procedures. Br J Haematol 2008; 140: 496-504.
14. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004; 164: 1319-1326.
15. Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost 2007; 5: 2211-2218.
16. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78: 2337-2343.
17. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900.
18. Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 1999; 84: 478-480.
19. Ansell JE. The perioperative management of warfarin therapy. Arch Intern Med 2003; 163: 881-883.
20. Ickx BE, Steib A. Perioperative management of patients receiving vitamin K antagonists. Can J Anesth 2006; 53(Suppl): S113-S122.
21. Jaffer AK, Ahmed M, Brotman DJ, Bragg L, Seshadri N, Qadeer MA et al. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. J Thromb Thrombolysis 2005; 20: 11-16.
22. Perry DJ, Nokes TJC, Heliwell PS. British Committee for Standards in Haematology. Guidelines for the management of patients on oral anticoagulants requiring dental surgery. 2007; http://www.bcshguidelines.com/pdf/ WarfarinandOralSurgery26407.pdf [accessed 9 February 2008].
23. Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L et al. Managing oral anticoagulant therapy. Chest 2001; 119(Suppl): 22S-38S.
24. Tinker JH, Tarhan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses. Observations in 180 operations. JAMA 1978; 239: 738-739.
25. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995; 122: 40-42.
26. Hewitt RL, Chun KL, Flint LM. Current clinical concepts in perioperative anticoagulation. Am Surg 1999; 65: 270-273.
27. Crowther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002; 137: 251-254.
28. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003; 163: 2469-2473.
29. Douketis JD. Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians. Thromb Res 2002; 108: 3-13.
30. Tinmouth AH, Morrow BH, Cruickshank MK, Moore PM, Kovacs MJ. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother 2001; 35: 669-674.
31. Kovacs M, Kahn S, Solymoss S, Anderson D, Desjardins L, Rodger M et al. Prospective multicentre trial of bridging therapy with dalteparin for patients who require temporary discontinuation of OAC for prosthetic valves or high risk atrial fibrillation. Blood 2003; 100: 149a (Abstract 559).
32. Turpie AG, Johnson J. Temporary discontinuation of oral anticoagulants: role of low molecular weight heparin (dalteparin). Circulation 2002; 100(Suppl): II-826 (Abstract 3983).
33. Jafri SM. Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy. Am Heart J 2004; 147: 3-15.
34. O'Donnell MJ, Kearon C, Johnson J, Robinson M, Zondag M, Turpie I et al. Brief communication: preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 2007; 146: 184-187.
35. Layton KF, Kallmes DF, Horlocker TT. Recommendations for anticoagulated patients undergoing image-guided spinal procedures. Am J Neuroradiol 2006; 27: 468-470.
36. Horlocker TT, Wedel DJ, Benzon H, Brown DL, Enneking FK, Heit JA et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003; 28: 172-197.
37. Hann CL, Streiff MB. The role of vena caval filters in the management of venous thromboembolism. Blood Rev 2005; 19: 179-202.
38. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a 'standard care' nomogram. A randomized controlled trial. Ann Intern Med 1993; 119: 874-881.
39. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(Suppl): 401S-428S.
40. Hassell K. The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy. Chest 2005; 127(Suppl): 1S-8S.
41. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; for the Beriplex® P/N Anticoagulation Reversal Study Group. Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008; 6: 622-631.
42. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77: 477-480.
43. Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 14: 458-461.
44. Pindur G, Morsdorf S. The use of prothrombin complex concentrates in the treatment of hemorrhages induced by oral anticoagulation. Thromb Res 1999; 95: S57-S61.
45. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 4: 967-970.
46. Spence RK. Clinical use of plasma and plasma fractions. Best Pract Res Clin Haematol 2006; 19: 83-96.
47. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev 2007; 21: 37-48.
48. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation annotation. Br J Haematol 2001; 114: 271-280.
49. van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 2006; 118: 313-320.
50. Josic D, Hoffer L, Buchacher A, Schwinn H, Frenzel W, Biesert L et al. Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity. Thromb Res 2000; 100: 433-441.
51. Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 2002; 116: 619-624.
52. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002; 137: 884-888.
53. Sun JC, Whitlock R, Cheng J, Eikelboom JW, Thabane L, Crowther MA et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J 2008; 29: 1057-1071.
54. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary (55th edn). British Medical Association and Royal Pharmaceutical Society of Great Britain: London, 2008.
55. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-847.
56. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47: 216-235.
57. Burger W, Chemnitius JM, Kneissl GD, Rücker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its preoperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med 2005; 257: 399-414.
58. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113: 2803-2809.
59. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-1521.
60. Murphy JT, Fahy BG. Thrombosis of sirolimus-eluting coronary stent in the postanesthesia care unit. Anesth Analg 2005; 101: 971-973.
61. Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE. Catastrophic outcomes of noncardiac surgery soon after coronary stenting, J Am Coll Cardiol 2000; 35: 1288-1294.
62. Schouten O, van Domburg RT, Bax JJ, de Jaegere PJ, Dunkelgrun M, Feringa HH et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol 2007; 49: 122-124.
63. Gershlick AH, Richardson G. Drug eluting stents. BMJ 2006; 333: 1233-1234.
64. Eikelboom JW, Hirsh J. Bleeding and management of bleeding. Eur Heart J Suppl 2006; 8(Suppl G): G38-G45.
65. Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49: 734-739.
66. Chassot PG, Delabays A, Spahn DR. Perioperative use of anti-platelet drugs. Best Pract Res Clin Anaesthesiol 2007; 21: 241-256.
67. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45: 456-459.
68. Charbucinska KN, Godet G, Itani O, Fleron MH, Bertrand M, Rienzo M et al. Anticoagulation management for patients with drug-eluting stents undergoing vascular surgery. Anesth Analg 2006; 103: 261-263.
69. Godet G, Le Manach Y, Lesache F, Perbet S, Coriat P. Drug-eluting stent thrombosis in patients undergoing non-cardiac surgery: is it always a problem? Br J Anaesth 2008; 100: 472-477.
70. Howard-Alpe GM, de Bono J, Hudsmith L, Orr WP, Foex P, Sear JW. Coronary artery stents and non-cardiac surgery. Br J Anaesth 2007; 98: 560-574.
71. Litz RJ, Gottschlich B, Stehr SN. Spinal epidural hematoma after spinal anesthesia in a patient treated with clopidogrel and enoxaparin. Anesthesiology 2004; 101: 1467-1470.
72. Tam NL, Pac-Soo C, Pretorius PM. Epidural haematoma after a combined spinal-epidural anaesthetic in a patient treated with clopidogrel and dalteparin. Br J Anaesth 2006; 96: 262-265.